Cited by 146Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876

Open access

Ma, Yibao, Wang, Wei, Idowu, Michael O., Oh, Unsong, Wang, Xiang-Yang, Temkin, Sarah M., Fang, Xianjun·2018·Cancers

DOI 10.3390/cancers11010033PMC PMC6356953

Open this paper in CoChat — free account Open PDF

Abstract

The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies. However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors. Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer. Notably, BAY-876 has not been evaluated in any cell or preclinical animal models since its discovery. We herein took advantage of BAY-876 and molecular approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis. The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models. Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells. BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs. These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer. BAY-876 is a potent blocker of GLUT1 activity, glycolytic metabolism and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers11010033

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

On the origin of cancer cells
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,719
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Jagt, D. L. V., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,528
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico‐Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,077
Glucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013

Flagged first, then by citations

Show all 51 references

Research works printed but not linked: 1

Warburg, 1924, üeber den Stoffwechsel der Tumoren, Biochem. Z., 152, 319

Sorted by citations

Items 101–146 of 146

Molecular Structure, Biochemical Functions, Genetics, and Emerging Clinical Relevance of Glucose Transporters
Jafri, S. S. Q., Shah, S. I. A., & Jaffari, S. H. A. (2023) · Global Journal of Medical Pharmaceutical and Biomedical Update · doi:10.25259/gjmpbu_56_2023 · Cited by 7
Starving the Devourer: Cutting Cancer Off from Its Favorite Foods
Katt, W. P., Lukey, M. J., & Cerione, R. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.09.005 · Cited by 7
Clinical application prospects of traditional Chinese medicine as adjuvant therapy for metabolic reprogramming in colorectal cancer
Zhexian, L., Xingqi, G., Xinxin, D., Tong, X., Ma, S., & Yanxi, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630279 · Cited by 7
Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer
Yan, J., Xu, F., Zhou, D., Zhang, S., Zhang, B., Meng, Q., & Lv, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1231460 · Cited by 8
CircRNA-regulated glucose metabolism in ovarian cancer: an emerging landscape for therapeutic intervention
Wang, Y., Chen, X., & Yang, Y. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03285-4 · Cited by 7
Breaking the vicious cycle: Multifunctional nanomaterials targeting Tumor metabolic reprogramming to overcome T cell exhaustion and bone repair failure in bone tumors
Guo, S., Yan, Z., Huang, Y., Hu, X., Zhang, H., Wang, Y., Zhang, T., Qiang, H., Xue, M., Gao, J., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102258 · Cited by 5
Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy
Kumari, S., Gupta, S., Jamil, A., Tabatabaei, D., & Karakashev, S. V. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31495 · Cited by 5
RAS: Circuitry and therapeutic targeting
Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 6
Lactic acid metabolism: gynecological cancer's Achilles’ heel
Zhang, T., Zhou, W., Fan, T., Yuan, Y., Tang, X., Zhang, Q., Zou, J., & Li, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02364-y · Cited by 4
Targeting the Glucose–Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth
Mazambani, S., Park, S.-H., Choe, J. H., Nguyen, A. H., Lee, B., Jeong, J. Y., Lee, S. Y., Kim, C., Park, Y., Padilla, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0506 · Cited by 4
Exploring the anticancer potential of hydrogen sulfide and BAY‑876 on clear cell renal cell carcinoma cells: Uncovering novel mutations in VHL and KDR genes among ccRCC patients
Hamadamin, P. S., & Maulood, K. A. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2719 · Cited by 4
BBOX1 mediates metabolic reprogramming driven by hypoxia and participates in the malignant progress of high-grade serous ovarian cancer
Huang, J., Tang, Y. C., Li, Y., Wei, W., Kang, F., Tan, S., Lin, L., Lu, X., Wei, H., & Wang, N. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119830 · Cited by 4
Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen‑125 secretion in ovarian carcinoma
Antoun, S., Atallah, D. M., Tahtouh, R., Assaf, M. D., Moubarak, M., Ayoub, E. N., Chahine, G. Y., & Hilal, G. (2019) · Oncology Letters · doi:10.3892/ol.2019.11233 · Cited by 4
The promising oncostatic effects of melatonin against ovarian cancer
Das, N. K., & Samanta, S. (2021) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v3i4.185 · Cited by 4
The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin
Zhao, Y., Li, X., Xu, S., Yang, Y., Chen, Q., Li, J., Tian, W., Zhang, Q., Hou, H., & Li, D. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23795 · Cited by 3
Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential
Verma, M., Mishra, P. S., Rahaman, S. A., Gupta, T., Sheikh, A. A., Sah, A. K., Sabrievna, V. A., Dzhuraevich, K. I., Abbas, A. M., Shalabi, M. G., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13081830 · Cited by 3
Targeting glycolytic enzymes to combat cancer metastasis: Strategies toward clinical translation
Zhang, D., He, Y., & He, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117499 · Cited by 2
In vivo magnetic resonance imaging of glucose via interfacial enzyme-catalyzed signal-amplifying probes
Yang, W., Wu, Z., Ouyang, R., Dai, C., Xu, Y., Wang, H., Yu, G., Zhu, P., Liu, D., Yun, Y., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100367 · Cited by 2
Lactate metabolic reprogramming and lactylation modification: molecular mechanisms reshaping the tumor immunosuppressive microenvironment
Yuan, Y., Gao, Y., Xue, J., Zhang, H., Liang, R., Huang, L., Wang, Z., Song, L., Qin, Y., & Ai, J. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01572-5 · Cited by 2
Activation of cellular antioxidative stress and migration activities by purified components from immortalized stem cells from human exfoliated deciduous teeth
Shu, Y., Otake, M., Seta, Y., Hori, K., Kuramochi, A., Ohba, Y., & Teramura, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-66213-8 · Cited by 2
Catechol-Ag interlayer constructed nanofiltration membrane for efficient purification of glucose from sugars
Ju, X., Gao, H. J., Wang, C., Li, R., Zhang, W., Ji, H., Xiao, X., Li, W., & Tong, Y. (2024) · Journal of Membrane Science · doi:10.1016/j.memsci.2024.123497 · Cited by 3
Recent Advances in Drug Development Targeting Cancer Metabolism
Sugandha, N., Mittal, L., Awasthi, A., & Asthana, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-1991-8_8 · Cited by 2
Nutrient-transporter driven cytotoxic potential: an emerging nanotherapeutic approach
Dighe, S., Manchanda, N., Sharma, S., & Jain, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104478 · Cited by 1
Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk
Zhang, Z.-H., Ding, Z.-Y., Luo-yi, C., Fu, Y.-X., & Huang, M. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01815-8 · Cited by 1
Glycolytic reprogramming in ovarian cancer: mechanisms, immune crosstalk, and therapeutic implications
Fu, J., Dai, Y., Wang, Q. H., & Qian, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1850399 · Cited by 1
EgGLUT1 is crucial for the viability of larvae of Echinococcus granulosus sensus lato by involving its glucose uptakePreprint
Amahong, K., Yan, M., Li, J., Yang, N., Liu, H., Bi, X., Vuitton, D. A., Lin, R., & Lü, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.02.438290
The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_3
DECOMPOSITION OF LINE-BROADENING CALCULATIONS INTO STATE-TO-STATE TERMS*
Flannery, C., Steinfeld, J. I., & Gamache, R. R. (1992) · The Knowledge Bank (The Ohio State University)
Correlation of SUVmax measured by 18 F-FDG PET/CT and expressions of glucose metabolism regulatory proteins in epithelial ovarian cancerPreprint
Yuan, X., Huang, R., Wang, Y., Tan, Y., & Fu, C. M. (2022) · Research Square · doi:10.21203/rs.3.rs-2016255/v1
Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
Guo, L., Zhang, W., Xie, Y., Chen, X., Olmstead, E. E., Lian, M., Zhang, B., Zaytseva, Y. Y., Evers, B. M., Spielmann, H. P., et al. (2023) · doi:10.1158/1535-7163.c.6543421.v1
Effects of selective lactate dehydrogenase A inhibitors and their mechanism in neoplastic and non-neoplastic cells
Frańczak, M. (2024) · doi:10.5463/thesis.984
Saccades orchestrate intraocular glucose to shape visual responses in birdsPreprint
Xu, X., Xiao, T., Chen, Y., Song, L., Wu, C., Wang, Q., Zhang, T., & Yang, Y. Q. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.17.649318
Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancerPreprint
Govindarajan, M., Waas, M., Meija-Guerrero, S., Lin, B., Ling, T., Li, X., Ignatchenko, V., Tikhonova, A. N., Jones, C. L., Ailles, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.02.673726
Additional file 1 of A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism
Shriwas, P., Roberts, D. A., Li, Y., Wang, L., Qian, Y., Bergmeier, S. C., Hines, J. V., Adhicary, S., Nielsen, C. M., & Chen, X. (2021) · Figshare · doi:10.6084/m9.figshare.14329567
Additional file 2 of A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism
Shriwas, P., Roberts, D. A., Li, Y., Wang, L., Qian, Y., Bergmeier, S. C., Hines, J. V., Adhicary, S., Nielsen, C. M., & Chen, X. (2021) · Figshare · doi:10.6084/m9.figshare.14329570
Disulfidptosis-based cancer therapy: Opportunity and challenge
Wang, B., Liu, Z., Li, J., Xu, J., Guo, Y., Zhang, J., Chu, T., Feng, Z., Jiang, Q., & Wu, D. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102028 · Cited by 1
Saccades orchestrate intraocular glucose dynamics to shape visual responses in birds
Xu, X., Xiao, T., Chen, Y., Song, L., Wu, C., Wang, Q., Zhang, T., & Yang, Y. (2026) · Nature Communications · doi:10.1038/s41467-026-70672-0
Solute carrier transporters in tumor metabolism and tumor immunity
Chen, M., Xu, J. F., Ma, H., Qin, J., Cheng, J., & Lv, J. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112084
Systematic Screening of a Glycolysis-targeting Small-molecule Library Identifies Novel Inhibitors of Fungal Morphogenesis in Candida albicansPreprint
Shah, D., Martoliya, Y., Mathivathanan, S., Shrivastava, A., Asthana, S., & Varahan, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.23.720332
Intermittent fasting synergizes with GCN5 inhibition to suppress RBM5-AS1/GCN5/PGC-1α–driven Warburg metabolism in ovarian cancer
Gunasangkaran, G., Muthukrishnan, S., Divya, R., Dhiva, S., Ravi, A. K., Arumugam, V. A., & Arockianathan, P. M. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01927-8
Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities
Iova, O.-M., Marin, G.-E., Răzniceanu, V., Mocrei-Rebrean, Ș.-M., Pintilie, S. R., Netea-Maier, R. T., & Berindan‐Neagoe, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125472
Preliminary evaluation of oxidative stress responses to withaferin-A in Plasmodium-infected erythrocytes and computational target screening
Pradhan, D., Biswasroy, P., Pradhan, D. K., Ramchandani, M., Ghosh, G., Rath, G., & Madhab, K. D. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100815
Concurrent Inhibition of AKT and GLUT1 Reveals Endpoint-Specific Effects on Glucose Metabolism and Cell Death in HepG2 Hepatocyte-Derived Cells
Asiri, A., Otaibi, A. A., Tasleem, M., Mubarak, S. A. S., Said, M. A., Mihmadi, Y. A. A., Subei, B. A., Asiri, A., Qarni, A. A., & Bakillah, A. (2026) · Biomedicines · doi:10.3390/biomedicines14092133
Lactate metabolism and protein lactylation in programmed cell death: From novel mechanism to therapeutic strategies in human diseases
Chen, Y., Wang, X., Wang, X., Lin, N., Wang, W., Fu, R., Wu, Y., Liu, Y., & Liu, H. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70795
Self-citation
Regulating the performance of the membranes based on oxidation-induced self-polymerization of di-amine and polyphenol through incorporation of sulfonic di-amine for glucose- KCl separation
Fatih, J. M., Wee, L. H., Yan, Z., Xu, M., Wang, C., & Li, Y. (2026) · Separation and Purification Technology · doi:10.1016/j.seppur.2026.140577
BindingDB Entry 50007948: The Druggability of Solute Carriers.
BindingDB (2021) · UC San Diego · doi:10.7270/q26113pd

Authors: Ma, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X.
Affiliations: Virginia Commonwealth University (US)
Corresponding author: Fang, Xianjun
ORCID: Ma, Yibao
Wang, Wei
Idowu, Michael O.
Oh, Unsong
Wang, Xiang-Yang
Temkin, Sarah M.
Fang, Xianjun
Venue: Cancers
Publisher: MDPI AG
Published: 2018-12-31
Volume: 11
Issue: 1
Pages: 33
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers11010033
PMC: PMC6356953
OpenAlex: W2907710771
Cited by: 145
References: 51
Citations by year: 2026: 14 · 2025: 15 · 2024: 21 · 2023: 25 · 2022: 18 · 2021: 27 · 2020: 9 · 2019: 14
FWCI: 3.85
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (P30 CA16059)
Astar Biotechnology Research award (N/A)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: ovarian cancer, glucose transporter 1, GLUT1, BAY-876, glycolysis, cancer metabolism, glycolysis inhibitors, tumor growth, patient-derived xenografts, anchorage-independent growth, anticancer activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks